Patterns of multispecialty care for low- and intermediate-risk prostate cancer in the use of active surveillance

被引:0
|
作者
Zambrano, Ibardo A. [1 ]
Hwang, Soohyun [2 ]
Basak, Ram [1 ]
Spratte, Brooke Namboodri [1 ]
Filson, Christopher P. [3 ]
Jacobs, Bruce L. [4 ]
Tan, Hung-Jui [1 ]
机构
[1] Univ N Carolina, Dept Urol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Hlth Policy & Management, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA
[3] Emory Univ, Dept Urol, Sch Med, Atlanta, GA USA
[4] Univ Pittsburgh, Dept Urol, Pittsburgh, PA USA
关键词
Prostate cancer; Active surveillance; SEER Medicare; Multispecialty care; Referral; Consultation; MODULATED RADIATION-THERAPY; UROLOGISTS; RECOMMENDATIONS; ONCOLOGISTS;
D O I
10.1016/j.urolonc.2023.04.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Multidisciplinary models of care have been advocated for prostate cancer (PC) to promote shared decision-making and facilitate quality care. Yet, how this model applies to low-risk disease where the preferred management is expectant remains unclear. Accordingly, we examined recent practice patterns in specialty visits for low/intermediate-risk PC and resultant use of active surveillance (AS). Methods: Using SEER-Medicare, we ascertained whether patients saw urology and radiation oncology (i.e., multispecialty care) versus urology alone, based on self-designated specialty codes, for newly diagnosed PC from 2010 to 2017. We also examined the association with AS, defined as the absence of treatment within 12 months of diagnosis. Time trends were analyzed using Cochran-Armitage test. Chi squared and logistic regression analyses were applied to compare sociodemographic and clinicopathologic characteristics between these models of care. Results: The proportion of patients seeing both specialists was 35.5% and 46.5% for low- and intermediate-risk patients respectively. Trend analysis showed a decline in multispecialty care in low-risk patients (44.1% to 25.3% years 2010-2017; P < 0.001). Between 2010 and 2017, the use of AS increased 40.9% to 68.6% (P < 0.001) and 13.1% to 24.6% (P < 0.001) for patients seeing urology and those seeing both specialists respectively. Age, urban residence, higher education, SEER region, co-morbidities, frailty, Gleason score, predicted receipt of multispecialty care (all P < 0.02). Conclusions: Uptake of AS among men with low-risk PC has occurred primarily under the purview of urologists. While selection is certainly at play, these data suggest that multispecialty care may not be required to promote the utilization of AS for men with low-risk PC. 0 2023 Elsevier Inc. All rights reserved.
引用
收藏
页码:388.e1 / 388.e8
页数:8
相关论文
共 50 条
  • [41] Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance
    Sherer, Michael, V
    Leonard, Austin J.
    Nelson, Tyler J.
    Guram, Kripa
    De Moraes, Gustavo Rodrigues
    Javier-Desloges, Juan
    Kane, Christopher
    McKay, Rana R.
    Rose, Brent S.
    Bagrodia, Aditya
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 50 : 61 - 67
  • [42] Active Surveillance of Low- Risk- Prostate Cancer
    Weissbach, L.
    UROLOGE, 2015, 54 (06): : 869 - 869
  • [43] Longitudinal regret after treatment for low- and intermediate-risk prostate cancer
    Hurwitz, Lauren M.
    Cullen, Jennifer
    Kim, Daniel J.
    Elsamanoudi, Sally
    Hudak, Jane
    Colston, Maryellen
    Travis, Judith
    Kuo, Huai-Ching
    Rice, Kevin R.
    Porter, Christopher R.
    Rosner, Inger L.
    CANCER, 2017, 123 (21) : 4252 - 4258
  • [44] Pure Hypofractionated Radiotherapy for the Treatment of Low- to Intermediate-Risk Prostate Cancer
    Stephens, R.
    Gopaul, D.
    Panjwani, D.
    Lock, M.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S732 - S732
  • [45] Current focal therapies for the treatment of low- and intermediate-risk prostate cancer
    Malorgio, Antonio
    ASIAN JOURNAL OF ANDROLOGY, 2024, 26 (06): : 592 - 594
  • [46] Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
    Kunogi, Hiroaki
    Wakumoto, Yoshiaki
    Kawamoto, Terufumi
    Oshima, Masaki
    Horie, Shigeo
    Sasai, Keisuke
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (06) : 554 - 561
  • [47] Clinical Case Discussion: Intermediate-risk Prostate Cancer: The Case for Active Surveillance
    Dall'Era, Marc A.
    Davies, Benjamin J.
    EUROPEAN UROLOGY FOCUS, 2015, 1 (02): : 208 - 209
  • [48] Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis
    Rashid K. Sayyid
    John Z. Benton
    William C. Reed
    Phillip Woodruff
    Martha K. Terris
    Christopher J. D. Wallis
    Zachary Klaassen
    World Journal of Urology, 2023, 41 : 93 - 99
  • [49] Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance
    Marra, Giancarlo
    Soeterik, Timo
    Oreggia, Davide
    Tourinho-Barbosa, Rafael
    Moschini, Marco
    Filippini, Claudia
    van Melick, Harm H. E.
    van den Bergh, Roderick C. N.
    Gontero, Paolo
    Cathala, Nathalie
    Macek, Petr
    Sanchez-Salas, Rafael
    Cathelineau, Xavier
    EUROPEAN UROLOGY FOCUS, 2022, 8 (03): : 701 - 709
  • [50] Prostate cancer mortality rates in low- and favorable intermediate-risk active surveillance patients: a population-based competing risks analysis
    Sayyid, Rashid K.
    Benton, John Z.
    Reed, William C.
    Woodruff, Phillip
    Terris, Martha K.
    Wallis, Christopher J. D.
    Klaassen, Zachary
    WORLD JOURNAL OF UROLOGY, 2023, 41 (01) : 93 - 99